These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28961677)

  • 21. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
    van der Straten A; Browne EN; Shapley-Quinn MK; Brown ER; Reddy K; Scheckter R; Soto-Torres L; Palanee-Phillips T; Baeten JM; Mensch B;
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):304-310. PubMed ID: 30844995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
    Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
    AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
    McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
    Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
    Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
    AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
    Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
    BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
    Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
    AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.
    das Neves J; Martins JP; Sarmento B
    Adv Drug Deliv Rev; 2016 Aug; 103():20-32. PubMed ID: 26732684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring.
    McCoy CF; Murphy DJ; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
    J Pharm Sci; 2017 Aug; 106(8):2015-2025. PubMed ID: 28456732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance and Acceptability of the FC2 Female Condom When Used With and Without a Silicone Placebo Vaginal Ring-A Randomized, Crossover Trial.
    Nel A; Malherbe M; van Niekerk N; Beksinska M; Greener R; Smit J; Frezieres R; Walsh T
    J Acquir Immune Defic Syndr; 2020 Sep; 85(1):58-65. PubMed ID: 32452973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial.
    Sugarman J; Lin L; Baeten JM; Palanee-Phillips T; Brown ER; Matovu Kiweewa F; Mgodi NM; Nair G; Siva S; Seils DM; Weinfurt KP;
    AJOB Empir Bioeth; 2019; 10(2):79-87. PubMed ID: 31002583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.
    Kusemererwa S; Abaasa A; Kabarambi A; Onyango M; Mugisha JO
    Sex Transm Infect; 2022 Feb; 98(1):32-37. PubMed ID: 33542153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
    Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
    PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.
    Gollub EL; Vaughan R
    AIDS Educ Prev; 2022 Aug; 34(4):311-324. PubMed ID: 35994576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
    Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
    J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.